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Re: CYP2D6 Genotype and 
Tamoxifen Response in 
Postmenopausal Women 
With Endocrine-Responsive 
Breast Cancer: The Breast 
International Group 1-98 Trial
two recent articles by regan et al. (1) and 
rae et al. (2), accompanied by an editorial (3), 
purport to settle the controversy of whether 
CYP2D6 genotype is associated with the 
pharmacodynamics of tamoxifen. there 
have been many previous studies, which vary 
in source of DNA (tumor, blood), pheno-
type (efficacy, toxicity, pharmacokinetics), 
general design (prospective, retrospective), 
concomitant medications (other antican-
cer medications, CyP2D6 inhibitors), and 
statistical approaches (4). A key issue in all 
genetic studies is the quality of the primary 
genetic data, as no inferences can be drawn 
from genotype data of low quality. In regard 
to the latter, a critical and fundamental first 
step in assessing the quality of genotypes is 
a test for deviation of the genotype distri-
bution from hardy–Weinberg equilibrium 
(hWe) (5), which should be considered 
of particular importance when DNA for 
genotyping has been extracted from tumor, 
rather than germline tissue. 
thus, it is of grave concern that one of 
the recent studies (1) shows clear evidence of 
massive departures from hWe; insufficient 
information was provided in the second 
study (2) to assess the quality of the geno-
type data. using the data in table 2 of the 
regan et al. study (1), the two most impor-
tant variants, rs3892097 and rs28371725, fail 
quality control, with unacceptable P values 
(from χ2 tests for consistency with hWe) of 
approximately 10−91 and 10−173, respectively. 
For both variants, there is an excess of 
homozygotes, consistent with the hypoth-
esis that hemizygous deletions of CYP2D6 
in tumors from which DNA samples were 
obtained may account for these flawed 
results. the estimated excess of homozy-
gotes is approximately 5% for each geno-
type, consistent with approximately 33% of 
tumor samples having CYP2D6 deletions. 
Because CYP2D6 is located on chromosome 
22q13 where frequent losses of heterozygo-
sity in breast cancer cells have been reported 
(6), it would not be surprising if CYP2D6 
were deleted in breast cancer. In addition, 
22q13 deletions have been associated with 
a worse prognosis, as exemplified by a large 
single-institution Japanese study in which 
32% of tumors had 22q13 deletions (7). 
thus, if a tumor from a patient who is a ger-
mline heterozygote loses one of the alleles, 
this causes misclassification of that patient’s 
tamoxifen metabolism phenotype. An alter-
native explanation, given the incomplete 
genotyping in these DNA samples, is that 
samples from heterozygotes are dispropor-
tionately not called (ie, the missing data are 
not missing at random). Genotyping of addi-
tional markers on chromosome 22q13 could 
distinguish these hypotheses. In any case, the 
genotype data from this study fail the most 
rudimentary quality tests, and therefore, we 
question its validity. Given the importance 
of the question being studied, we urge the 
retraction of the regan et al. study (1).
We also urge reanalysis of other stud-
ies that have utilized tumor DNA for 
genotyping, given the potential for hemizy-
gous deletion of CYP2D6 in breast cancer. 
hopefully, this will be another important 
“lesson learned” for investigators in breast 
cancer genomics (3). the goal of personal-
ized medicine is to provide an appropriate 
dose of the optimal drug to each individual 
patient, but it is critical that quality data 
from rigorous studies be used to inform 
these decisions. 
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